Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
491 of 621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleClinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05363722 - Phase 2Taking peopleCryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 180
- Run by
- Fudan University
See details and how to joinNCT07829874 - Phase 1Taking peoplePhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Where
- Nanjing, Shanghai
- Age
- 18 years to 75 years
- People
- 70
- Run by
- Acepodia Biotech, Inc.
See details and how to joinNCT07861425 - Phase 3Taking peopleZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
- Where
- Nanjing
- Age
- 18 years and over
- People
- 600
- Run by
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT07813572 - Phase 1/2Taking peopleSumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
- Where
- Beijing
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Full-Life Technologies UK Limited
See details and how to joinNCT07873450 - Phase 2Not yet taking people in ChinaHLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
- Where
- Wuhan
- Age
- 18 years and over
- People
- 128
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07938021 - Phase 2Not yet taking people in ChinaA Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 43
- Run by
- Fujian Cancer Hospital
See details and how to joinNCT07940478 - No phaseTaking peopleGoal-directed LCVP Based on HP in Laparoscopic Hepatectomy
- Where
- Nanjing
- Age
- 18 years and over
- People
- 160
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05887661 - Phase 2Taking peopleNeoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
- Where
- Jinan, Jingmen, Nanning, Qingdao, Shanxi, Shiyan, Xiangyang, Zhengzhou
- Age
- 18 years to 75 years
- People
- 160
- Run by
- Chen Xiaoping
See details and how to joinNCT06420440 - Phase 2Taking peopleEpalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
- Where
- Harbin, Shenyang, Yanji
- Age
- 18 years to 80 years
- People
- 32
- Run by
- Haibo Shao
See details and how to joinNCT07557914 - No phaseTaking peoplePreoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
- Where
- Guangzhou
- Age
- 18 years to 80 years
- People
- 33
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07326189 - Phase 2Not yet taking people in ChinaNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07919717 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1Not yet taking people in ChinaA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - Phase 3Not yet taking people in ChinaHepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 90
- Run by
- Zhai Wenlong
See details and how to joinNCT07916844 - No phaseTaking peoplePhotodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable Extrahepatic Cholangiocarcinoma
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 30
- Run by
- Zhai Wenlong
See details and how to joinNCT07916870 - No phaseNot yet taking people in ChinaProspective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT
- Where
- Beijing
- Age
- 18 years and over
- People
- 10,000
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07911397 - Phase 2/3Taking peopleA Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 66
- Run by
- Guangzhou Virotech Pharmaceutical Co., Ltd.
See details and how to joinNCT07589244 - Phase 1/2Taking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 3Not yet taking people in ChinaA Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
- Where
- Nanjing, Shanghai
- Age
- 18 years to 75 years
- People
- 690
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07691762 - Phase 3Taking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Harbin, Hefei, Jinan, Lanzhou, Shanghai
- Age
- 18 years and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - Phase 2Taking peoplePerioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 81
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07847710 - Phase 2Taking peopleTACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 105
- Run by
- Sun Yat-sen University
See details and how to joinNCT07487662 - Phase 3Not yet taking people in ChinaIntraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
- Where
- Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Jiangmen, Jinan, Jinhua, Lishui, Ningbo, Qingdao, Ürümqi, Wuhan
- Age
- 18 years and over
- People
- 140
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07691515